145 related articles for article (PubMed ID: 1558978)
1. A comparison of the iron-clearing properties of 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-diethyl-3-hydroxypyrid-4-one, and deferoxamine.
Bergeron RJ; Streiff RR; Wiegand J; Luchetta G; Creary EA; Peter HH
Blood; 1992 Apr; 79(7):1882-90. PubMed ID: 1558978
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the iron-clearing properties of desferrithiocin analogues with desferrioxamine B in a Cebus monkey model.
Bergeron RJ; Streiff RR; Creary EA; Daniels RD; King W; Luchetta G; Wiegand J; Moerker T; Peter HH
Blood; 1993 Apr; 81(8):2166-73. PubMed ID: 8471775
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the iron-clearing properties of parabactin and desferrioxamine.
Bergeron R; Streiff RR; King W; Daniels RD; Wiegand J
Blood; 1993 Oct; 82(8):2552-7. PubMed ID: 8400302
[TBL] [Abstract][Full Text] [Related]
4. Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.
Morel I; Cillard J; Lescoat G; Sergent O; Pasdeloup N; Ocaktan AZ; Abdallah MA; Brissot P; Cillard P
Free Radic Biol Med; 1992 Nov; 13(5):499-508. PubMed ID: 1334028
[TBL] [Abstract][Full Text] [Related]
5. Studies of in vivo iron mobilization by chelators in the ferrocene-loaded rat.
Florence A; Ward RJ; Peters TJ; Crichton RR
Biochem Pharmacol; 1992 Sep; 44(6):1023-7. PubMed ID: 1417929
[TBL] [Abstract][Full Text] [Related]
6. Ability of the orally effective iron chelators dimethyl- and diethyl-hydroxypyrid-4-one and of deferoxamine to restore sarcolemmal thiolic enzyme activity in iron-loaded heart cells.
Link G; Pinson A; Hershko C
Blood; 1994 May; 83(9):2692-7. PubMed ID: 8167347
[TBL] [Abstract][Full Text] [Related]
7. Effective chelation of iron in beta thalassaemia with the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one.
Kontoghiorghes GJ; Aldouri MA; Hoffbrand AV; Barr J; Wonke B; Kourouclaris T; Sheppard L
Br Med J (Clin Res Ed); 1987 Dec; 295(6612):1509-12. PubMed ID: 3122880
[TBL] [Abstract][Full Text] [Related]
8. Effect of iron overload on the metabolism and urinary recovery of 3-hydroxypyridin-4-one chelating agents in the rat.
Choudhury R; Singh S
Drug Metab Dispos; 1995 Mar; 23(3):314-20. PubMed ID: 7628295
[TBL] [Abstract][Full Text] [Related]
9. Origin and fate of iron mobilized by the 3-hydroxypyridin-4-one oral chelators: studies in hypertransfused rats by selective radioiron probes of reticuloendothelial and hepatocellular iron stores.
Zevin S; Link G; Grady RW; Hider RC; Peter HH; Hershko C
Blood; 1992 Jan; 79(1):248-53. PubMed ID: 1728313
[TBL] [Abstract][Full Text] [Related]
10. Iron chelation studies using desferrioxamine and the potential oral chelator, 1,2-dimethyl-3-hydroxypyrid-4-one, in normal and iron loaded rats.
Kontoghiorghes GJ; Sheppard L; Hoffbrand AV; Charalambous J; Tikerpae J; Pippard MJ
J Clin Pathol; 1987 Apr; 40(4):404-8. PubMed ID: 3584483
[TBL] [Abstract][Full Text] [Related]
11. Iron-balance and dose-response studies of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in iron-loaded patients with sickle cell disease.
Collins AF; Fassos FF; Stobie S; Lewis N; Shaw D; Fry M; Templeton DM; McClelland RA; Koren G; Olivieri NF
Blood; 1994 Apr; 83(8):2329-33. PubMed ID: 8161801
[TBL] [Abstract][Full Text] [Related]
12. Dose response studies using desferrioxamine and orally active chelators in a mouse model.
Kontoghiorghes GJ
Scand J Haematol; 1986 Jul; 37(1):63-70. PubMed ID: 3764334
[TBL] [Abstract][Full Text] [Related]
13. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy.
Bergeron RJ; Wiegand J; Brittenham GM
Blood; 1999 Jan; 93(1):370-5. PubMed ID: 9864183
[TBL] [Abstract][Full Text] [Related]
14. Biliary and urinary metabolic profiles of 1,2-diethyl-3-hydroxypyridin-4-one (CP94) in the rat.
Lu SL; Gosriwatana I; Liu DY; Liu ZD; Mallet AI; Hider RC
Drug Metab Dispos; 2000 Aug; 28(8):873-9. PubMed ID: 10901694
[TBL] [Abstract][Full Text] [Related]
15. Urinary metabolic profiles in human and rat of 1,2-dimethyl- and 1,2-diethyl-substituted 3-hydroxypyridin-4-ones.
Singh S; Epemolu RO; Dobbin PS; Tilbrook GS; Ellis BL; Damani LA; Hider RC
Drug Metab Dispos; 1992; 20(2):256-61. PubMed ID: 1352218
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and iron(III) binding properties of 3-hydroxypyrid-4-ones derived from kojic acid.
Molenda JJ; Basinger MA; Hanusa TP; Jones MM
J Inorg Biochem; 1994 Aug; 55(2):131-46. PubMed ID: 8051541
[TBL] [Abstract][Full Text] [Related]
17. Chelation of aluminium by combining DFO and L1 in rats.
Blanusa M; Prester L; Varnai VM; Pavlović D; Kostial K; Jones MM; Singh PK
Toxicology; 2000 Jul; 147(3):151-6. PubMed ID: 10924797
[TBL] [Abstract][Full Text] [Related]
18. Modulation by iron loading and chelation of the uptake of non-transferrin-bound iron by human liver cells.
Parkes JG; Randell EW; Olivieri NF; Templeton DM
Biochim Biophys Acta; 1995 Apr; 1243(3):373-80. PubMed ID: 7727512
[TBL] [Abstract][Full Text] [Related]
19. Contrasting interspecies efficacy and toxicology of 1,2-diethyl-3-hydroxypyridin-4-one, CP94, relates to differing metabolism of the iron chelating site.
Porter JB; Abeysinghe RD; Hoyes KP; Barra C; Huehns ER; Brooks PN; Blackwell MP; Araneta M; Brittenham G; Singh S
Br J Haematol; 1993 Sep; 85(1):159-68. PubMed ID: 8251385
[TBL] [Abstract][Full Text] [Related]
20. Biliary excretion of plasma non-transferrin-bound iron in rats: pathogenetic importance in iron-overload disorders.
Brissot P; Zanninelli G; Guyader D; Zeind J; Gollan J
Am J Physiol; 1994 Jul; 267(1 Pt 1):G135-42. PubMed ID: 8048526
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
